Sign up
Pharma Capital

Tissue Regenix chief Antony Odell on their 'transformational' Cellright acquisition

Antony Odell, chief executive of Tissue Regenix PLC (LON:TRX) tells Proactive they're spending US$30mln on Texas-based rival, Cellright Technologies, which will catapult them to the front of  the growing US market for regenerative medicine and bone grafts.

 

View full TRX profile

Tissue Regenix Group PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.